<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04629235</url>
  </required_header>
  <id_info>
    <org_study_id>170430</org_study_id>
    <nct_id>NCT04629235</nct_id>
  </id_info>
  <brief_title>Reduction of Bedrest Time of Post Percutaneous Renal Biopsy Patients</brief_title>
  <acronym>RUBBY</acronym>
  <official_title>Reduction of Bedrest Time of Post Percutaneous Renal Biopsy Patients (RBP) Evaluated by Nursing Outcomes Classification (NOC): a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the reduction of the bedrest time of the patient after percutaneous renal biopsy&#xD;
      from 24 hours to 8 hours in relation to the occurrence of complications evaluated by the&#xD;
      Nursing Outcome Classification (NOC) indicators.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous renal biopsy (BRP) is an important procedure for the diagnosis, prognostic&#xD;
      evaluation and therapeutic orientation of several kidney diseases. Although it is considered&#xD;
      a safe procedure, BRP complications can occur and, most of the time, are related to the risk&#xD;
      of bleeding and the main consequence of BRP. Complications include macroscopic hematuria and&#xD;
      hematoma requiring blood transfusion, surgical intervention, or invasive procedure. Since&#xD;
      hemorrhagic complications continue to be the highest risk after BRP due to severity and&#xD;
      potential life-threatening risk, there is an effort to minimize the risk of bleeding by&#xD;
      checking blood clotting markers prior to the procedure, uncontrolled hypertension and the use&#xD;
      of antiplatelet drugs and anticoagulants. The relevance of this study is to seek better&#xD;
      evidence for clinical practice, considering the lack of Brazilian studies on the subject and&#xD;
      the positive impact on patient comfort, besides the reduction of costs for the institution&#xD;
      and overload in the work of the multidisciplinary team. In addition, it will contribute to&#xD;
      the strengthening of the use of NOC in clinical practice and to the improvement of nursing&#xD;
      knowledge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NOC Blood coagulation (0409)</measure>
    <time_frame>24 hours</time_frame>
    <description>The primary outcome will be constituted of the absence of bleeding, measured according to the clinical indicators Bleeding (040902), Bruising (040903) and Hematuria (040918). Checked by visual inspection at the puncture location. Check hematuria by visual inspection and test with reagent strips. Evaluated by Likert scale, being 1 the worst score and 5 best score.&#xD;
NOC Blood loss severity (0413): Meansurement of indicators Abdominal distension (041306) and Skin and mucous membrane pallor (041313). Assess the abdominal distension of the patient in the supine position, through inspection and palpation. Assess pallor by inspecting the extremities and mucous membranes, associated with the evaluation of capillary filling with the compression/decompression of the pulp of one or more digits. Evaluated by Likert scale, being 1 the worst score and 5 best score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NOC Circulation status (0401)</measure>
    <time_frame>24 hours</time_frame>
    <description>Measurement of Systolic blood pressure (040101) and Diastolic blood pressure (040102) with an inflatable cuff. Evaluated by Likert scale, being 1 the worst score and 5 best score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NOC Pain level (2102) as assessed by Visual Analog Pain Scale or Numerical Verbal Pain Scale, asking how much they rate their pain from 0 to 10</measure>
    <time_frame>24 hours</time_frame>
    <description>The improvement of the indicators Reported pain (210201) and Facial expressions of pain (210206). Question the patient about their pain level using a Visual Analog Pain Scale or Numerical Verbal Pain Scale, asking how much they rate their pain from 0 to 10. Evaluated by Likert scale, being 1 the worst score and 5 best score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NOC Comfort status: physical (2010)</measure>
    <time_frame>24 hours</time_frame>
    <description>Maintenance of Physical well-being (201002) and Comfortable position (201004). Question the patient about physical well-being and see if he has characteristics, for example: good physical mobility; feels comfortable; normal breathing; absence or control of pain. Ask the patient if he is comfortable with his body position. Check the need to use non-pharmacological (pillow, cushion, etc.) and/or pharmacological methods to be able to position yourself comfortably. Evaluated by Likert scale, being 1 the worst score and 5 best score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Bedrest</condition>
  <arm_group>
    <arm_group_label>24 hours of bedrest</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>- 24 hours of bedrest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Wonder around after 8 hours of bedrest</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>wonder around</intervention_name>
    <description>wonder around after 8 hours of bedrest</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>bedrest</intervention_name>
    <description>24 hours of bedrest</description>
    <arm_group_label>24 hours of bedrest</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients undergoing renal biopsy at Hospital de Clínicas de Porto Alegre (HCPA);&#xD;
&#xD;
          -  Both sexes;&#xD;
&#xD;
          -  Aged 18 years or older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with the following risk factors for complications;&#xD;
&#xD;
          -  More than two punctures during the procedure;&#xD;
&#xD;
          -  Larger gauge needle;&#xD;
&#xD;
          -  Uncontrolled blood pressure;&#xD;
&#xD;
          -  Blood clotting disorders and use of antiplatelet agents (aspirin or clopidogrel), or&#xD;
             use of anticoagulants;&#xD;
&#xD;
          -  Bedridden patients and patients unable to adequately to ambulate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amália de Fátima Lucena</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magáli Costa Oliveira</last_name>
    <phone>+5551982378146</phone>
    <email>magali_oliveirac@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amália de Fátima Lucena</last_name>
    <phone>+5551981794710</phone>
    <email>afatimalucena@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Biopsy</keyword>
  <keyword>Complications</keyword>
  <keyword>Standardized Nursing Terminology</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

